Selected Publications by Medaffcon Oy
These articles, posters and study abstracts represent a subset of the biobank and other real world evidence -based studies conducted by Medaffcon.
Peer-reviewed articles
Real-world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction, Huusko J, Purmonen T, Toppila I, Lassenius M and Ukkonen H. ESC Heart Failure (2020) DOI: 10.1002/ehf2.12665. https://onlinelibrary.wiley.com/doi/full/10.1002/ehf2.12665
Cardiovascular event rates increase after each recurrence and associate with poor statin adherence, Lassenius MI, Toppila I, Bergius S, Perttilä J, Airaksinen KEJ and Pietilä M. European Journal of Preventive Cardiology (2020) DOI: 10.1177/2047487320904334. https://doi.org/10.1177/2047487320904334
Burden of migraine in Finland: multimorbidity and phenotypic disease networks in occupational healthcare, Korolainen MA, Tuominen S, Kurki S, Lassenius MI, Toppila I, Purmonen T, Santaholma J and Nissilä M. The Journal of Headache and Pain (2020) 21:8. DOI: 10.1186/s10194-020-1077-x. https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-020-1077-x
Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis, Lassenius MI, Toppila I, Pöntynen N, Kasslin L, Kaunisto J, Kilpeläinen M and Laitinen T. European Clinical Respiratory Journal (2019) 7:1, 1702618, DOI: 10.1080/20018525.2019.1702618. https://www.tandfonline.com/doi/full/10.1080/20018525.2019.1702618
The Burden Of Chronic Obstructive Pulmonary Disease (COPD) In Finland: Impact Of Disease Severity And Eosinophil Count On Healthcare Resource Utilization, Viinanen A, Lassenius MI, Toppila I, Karlsson A, Veijalainen L, Idänpään-Heikkilä JJ and Laitinen T. International Journal of Chronic Obstructive Pulmonary Disease (2019) 14:2409-2421. https://www.dovepress.com/the-burden-of-chronic-obstructive-pulmonary-disease-copd-in-finland-im-peer-reviewed-article-COPD
The burden of adult asthma in Finland: impact of disease severity and eosinophil count on health care resource utilization, Viinanen A, Lassenius M, Toppila I, Karlsson A, Veijalainen L, Idänpään-Heikkilä J and Laitinen T. Journal of Asthma (2019). DOI: 10.1080/02770903.2019.1633664. https://www.tandfonline.com/doi/full/10.1080/02770903.2019.1633664
Heart failure in Finland: clinical characteristics, mortality, and healthcare resource use, Huusko J, Kurki S, Toppila I, Purmoen T, Lassenius M, Gullberg E, Bruce-Wirta S and Ukkonen H. ESC Heart Failure (2019). DOI: 10.1002/ehf2.12443. https://www.ncbi.nlm.nih.gov/pubmed/31054212
Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care, Korolainen M, Kurki S, Lassenius M, Toppila I, Costa-Scharplatz M, Purmonen T and Nissilä M. Journal of headache and pain (2019) 20:13. DOI: 10.1186/s10194-019-0964-5. https://rdcu.be/bmtGA
Type 2 diabetes and treatment intensification in primary care in Finland, Niskanen L, Hahl J, Haukka J, Leppä E, Miettinen T, Mushnikov V, Sipilä R, Tamminen N, Vattulainen P and Korhonen P. Acta Diabetologica (2018) 55:1171-1179. https://www.ncbi.nlm.nih.gov/pubmed/30083982
Health care resource utilization and characteristics of patients with eosinophilic asthma in secondary health care in Finland, Mäkelä MJ, Christensen HN, Karlsson A, Rastogi S and Kettunen K. European Clinical Respiratory Journal (2018) 5(1):1458560. https://www.ncbi.nlm.nih.gov/pubmed/29696083
Posters or oral presentations at international congresses
The real-world dose differences of insulin glargine 300 U/ml in Finland. Koski L, Hahl J, Kaye S & Pousar K. ISPOR Europe, Nov 2019, Copenhagen, Denmark. https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3120/94970
Migraine comorbidity and phenotypic disease networks in occupational health care. Korolainen M A, Kurki S, Tuominen S, Toppila I, Lassenius M I, Santaholma J, Purmonen T, Nissilä M. 19th Congress of the International Headache Society, Sep 7-8, 2019; Dublin, Ireland.
Study to determine predictive potential of an algorithm for earlier diagnosis of Gaucher disease: Retrospective biobank study utilizing real-world data available in Finland. Savolainen M, Karlsson A, Toppila I, Elomaa K, Panahloo Z, Wolf M. 15th Annual WORLD Symposium, Feb 4-8, 2019; Orlando, Florida, USA.
Health Registry Data Survey for Assessing Characteristics and Descriptive Epidemiology of Patients with Multiple Myeloma in Southwest Finland between 2004—May 2017. Salmi T, Saukkonen K, Wolf, M, Toppila I, Kurki S, Schoonen M, Putkonen M. ESH, 4th International Conference on multiple myeloma, Oct 5-7, 2018; Mandelieu, France.
Health care resource use, sick-leaves and comorbidities among migraine patients in occupational healthcare. Korolainen M A, Kurki S, Toppila I, Lassenius M, Purmonen T, Nissilä M. European Headache federation meeting, Sep 28-30, 2018; Florence, Italy.
Heart Failure in Finland – Evaluating the burden of disease and treatment patterns. Huusko J, Kurki S, Toppila I, Purmonen T, Lassenius M, Gullberg E, Bruce-Wirta S, Ukkonen H. European Society of Cardiology Congress, 2018; Munich, Germany. https://esc365.escardio.org/Congress/ESC-Congress-2018/Poster-Session-6-Chronic-heart-failure-epidemiology-prognosis-outcome/179342-heart-failure-in-finland-evaluating-the-burden-of-disease-and-treatment-patterns
Trend towards longer time to reimbursement in oncological medicines in Finland 2005-2015. Oinonen L, Renlund M, Pudas H, Ihalmo P, Hahl J. ISPOR, 2016. https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-19th-annual-european-congress/trend-towards-longer-time-to-reimbursement-in-oncological-medicines-in-finland-2005-2015
The epidemiology of adult immune (idiopathic) thrombocytopenic purpura (ITP) in Finland: resource utilisation, related costs and hospital medication associated with the treatment of non-splenectomised adult ITP based on real world data from Auria biobank. Kosunen M, Kurki S, Snicker K, Wiik E. ISPOR, 2017. https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-20th-annual-european-congress/the-epidemiology-of-adult-immune-idiopathic-thrombocytopenic-purpura-itp-in-finland-resource-utilisation-related-costs-and-hospital-medication-associated-with-the-treatment-of-non-splenectomised-adult-itp-based-on-real-world-data-from-auria
Resource utilisation and related health care costs among patients with multiple myeloma with ≥ 2 prior lines of treatment in Finland: evaluation based on Finnish real world data from Auria biobank. Kosunen M, Kurki S, Snicker K, Wiik E. ISPOR, 2017. https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-20th-annual-european-congress/resource-utilisation-and-related-health-care-costs-among-patients-with-multiple-myeloma-with-2-prior-lines-of-treatment-in-finland-evaluation-based-on-finnish-real-world-data-from-auria-biobank
Resource use, health care costs and burden of disease in patients with polycythemia vera in Finland: evaluation based on leukocyte counts using Finnish real world data from Auria biobank. Kosunen M, Kurki S, Snicker K, Wiik E. ISPOR, 2017. https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-20th-annual-european-congress/resource-use-health-care-costs-and-burden-of-disease-in-patients-with-polycythemia-vera-in-finland-evaluation-based-on-leukocyte-counts-using-finnish-real-world-data-from-auria-biobank
Cost-effectiveness of Pasireotide long-acting in a treatment of acromegaly in Finland. Economic evaluation based on Finnish Auria biobank data on health care resource utilization. Hahl J, Kurki S, Miettinen T, Snicker K. ISPOR, 2015. https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-18th-annual-european-congress/cost-effectiveness-of-pasireotide-long-acting-in-a-treatment-of-acromegaly-in-finland-economic-evaluation-based-on-finnish-auria-biobank-data-on-health-care-resource-utilization
Other
Lääkkeiden riskinjakosopimukset Suomen sairaaloissa – kyselytutkimus 2019. Honkanen H, Snicker K and Ahlamaa J. Suomen Lääkärilehti 2019; 49:2872 – 2876.
Tutkimuksen uudet mahdollisuudet on huomioitava biopankkilaissa. Tuompo W, Hemmilä P, Ahlamaa J and Wolf M. Finnish Medical Journal (2018) 37: 2006-2007.